Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended January 31, 2016. The filing’s financial statements compare the quarter and year-to-date periods with the corresponding 2015 periods. Amounts below are in U.S. dollars; financial statement amounts are generally in thousands unless stated otherwise.
Business context
Champions Oncology develops and sells oncology research and treatment-personalization services using its TumorGraft platform. Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. The company reported two operating segments, POS and TOS, and said it plans to expand the platform and both businesses.
Financial performance and liquidity
| Metric | Three months ended Jan. 31, 2016 | Three months ended Jan. 31, 2015 | Nine months ended Jan. 31, 2016 | Nine months ended Jan. 31, 2015 |
|---|---|---|---|---|
| Revenue | $2.552 million | $1.829 million | $8.345 million | $5.622 million |
| Operating loss | $2.373 million | $3.419 million | $7.767 million | $10.834 million |
| Net loss | $2.412 million | $2.816 million | $7.872 million | $9.463 million |
| Basic and diluted loss per share | $0.28 | Basic $0.51; diluted $0.61 | $0.90 | Basic $1.70; diluted $1.94 |
- Revenue increased 39.5% for the quarter and 48.4% for the nine months. TOS revenue rose 55.2% and 59.0%, respectively; POS revenue fell 8.2% in the quarter but rose 11.4% year to date.
- For the quarter, reported segment gross margins were negative 15.1% for POS and 23.8% for TOS, compared with negative 48.8% and 5.5% in 2015. For nine months, they were negative 19.8% and 32.7%, versus negative 75.9% and 26.3%.
- Cash and cash equivalents were $3.293 million at January 31, 2016, down from $9.357 million at April 30, 2015. Nine-month operating cash use was $5.853 million, compared with $7.622 million in 2015; investing cash use was $176,000. Financing used $35,000, versus $1.997 million provided in the prior-year period.
- Working capital was positive $1.2 million. Current assets were $5.812 million and current liabilities $4.647 million. Total liabilities were $4.886 million; the filing reports an $88,000 capital-lease obligation, including current and long-term portions, and no off-balance-sheet debt.
- Total assets were $7.145 million and stockholders’ equity $2.259 million at January 31, 2016. Cash-flow and balance-sheet values are reported in thousands.
Changes, outlook, and risks
- Management attributed TOS growth to a greater number and size of studies, following sales-team expansion and platform growth. POS sequencing revenue increased, while implant and panel revenue declined.
- Management said POS margin improvement reflected higher-margin sequencing revenue and lab-cost management; TOS margin improvement reflected revenue growth leveraging fixed lab costs and control of variable costs.
- Research and development expense fell 19.7% year to date, primarily due to lower TumorGraft Bank genomic-characterization costs. Sales and marketing expense fell 19.5%, reflecting consolidation of POS and TOS commercial resources. General and administrative expense rose 3.0%, primarily due to higher CEO and President stock-based compensation.
- Management believed January 31 cash would fund operations through at least April 2017. It warned that continued operations beyond that point may require external financing; unavailable or unacceptable financing could require cuts or delays to research and development and other activities. Management expected operating losses to continue until revenue grows substantially.
- The prior-year periods included gains from changes in warrant-liability fair value; the filing says the warrants were reclassified to equity. This contributed to lower reported other income in 2016 and affects period comparisons.
- The company reported no current legal proceedings. It had not accrued potential registration-rights penalties because management did not consider payment probable. Unrecognized tax liabilities were approximately $165,000. A one-for-twelve reverse stock split became effective August 12, 2015; share and per-share data were retrospectively adjusted.
- Management concluded disclosure controls were effective as of January 31, 2016 and reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue growth—particularly TOS study bookings—continues and translates into sustainable positive segment and consolidated margins.
- Actual cash burn, collections, and deferred-revenue performance relative to the stated runway through at least April 2017.
- Financing needs, availability, terms, and potential equity dilution or debt obligations if additional capital is required.
- The drivers and sustainability of POS sequencing growth and the decline in implant and panel revenue.
- Potential registration-rights penalties, tax exposures, and other contingencies, including whether their likelihood or estimated amounts change.